Skip to page content

Genomic Medicine

News Release
COG-UK Consortium's Pathogen Genomics Expertise Played Important Role in UK Response to COVID-19; Valuable Contribution to Public Health Genomics Should Not Be Lost
The COVID-19 Genomics UK (COG-UK) Consortium's efforts to sequence and understand the diverse variants of the SARS-CoV-2 virus, which causes COVID-19, have been key to informing public health decisionmaking and efforts to control its spread.
Feb 15, 2022
Report
COVID-19 Genomics UK (COG-UK) Consortium: Final Report
RAND Europe evaluated how the COVID-19 Genomics UK (COG-UK) Consortium contributed to the pandemic response in the United Kingdom and examined the role of pathogen genomics research and sequencing networks in pandemic response.
Feb 15, 2022
Journal Article
Demonstrating Trustworthiness When Collecting and Sharing Genomic Data: Views Across 22 Countries
We examine how participants from 22 countries perceived the relative value of measures to demonstrate the trustworthiness of those using donated DNA and/or medical information.
Feb 10, 2022
Journal Article
Members of the Public in the USA, UK, Canada and Australia Expressing Genetic Exceptionalism Say They Are More Willing to Donate Genomic Data
This paper examines how acceptance of data sharing pertains to the perceived similarities and differences between DNA and other forms of personal data.
Feb 10, 2022
Journal Article
Return of Genomic Results Does Not Motivate Intent to Participate in Research for All: Perspectives Across 22 Countries
The aim of this study was to determine how attitudes toward the return of genomic research results vary internationally.
Feb 8, 2022
Report
Technological Approaches to Human Performance Enhancement
Human performance enhancement (HPE) will have implications for military and intelligence operations. A variety of HPE could be of potential military and intelligence operational value. What are some approaches to HPE?
Nov 23, 2021
Commentary
Commercialisation and Open Science Do Not Have to Be Uneasy Bedfellows
On the surface, tension exists between commercialization and open science approaches to research. But the two approaches are not irreconcilable—they can exist in harmony and complement one another to generate greater impact from investments in research and innovation.
Aug 6, 2021
Journal Article
B-cell Lymphoma and Non-Hodgkin's Lymphoma Treatment: How Do Participants of Chimeric Antigen Receptor T-cell (CAR-T) Therapy Research Studies Compare With Patients in the US Population?
Chimeric antigen receptor (CAR)-T-cell therapy appears to be a promising treatment for B-cell and non-Hodgkin's lymphoma. CAR-T therapy effectiveness in the general population of patients may differ from effectiveness demonstrated in trials.
Jun 17, 2021
Journal Article
An Evidence Map of Randomised Controlled Trials Evaluating Genetic Therapies
This evidence map provides a broad overview of the genetic therapies that have been evaluated in randomised controlled trials for efficacy and safety.
Mar 12, 2021
Report
What Is the Value of Invention?
Inventions help people around the world live longer, healthier, and more-productive lives. The inventions of Lemelson-MIT Prize winners illustrate the scientific, technological, economic, and social effects that inventions can have on society.
Feb 11, 2021
Journal Article
Global Public Perceptions of Genomic Data Sharing: What Shapes the Willingness to Donate DNA and Health Data?
Analyzing genomic data across populations is central to understanding the role of genetic factors in health and disease. This paper presents results from a very large public survey on attitudes toward genomic data sharing.
Sep 22, 2020
Commentary
Ethics of Germline Editing Must Keep Up with Technology
Mainstream interest in genome editing is now surging. If this research is to go forward, the science should be well understood by those conducting the research. Best practices and the highest scientific standards should be employed to limit risks and prevent unintended consequences.
Jan 10, 2019
Report
Best Practices for Participant and Stakeholder Engagement in the All of Us Research Program
RAND researchers identified best practices for engaging participants in the All of Us Research Program, which collects long-term health data from 1 million U.S. adults. Engagement involves awareness, enrollment, and retention of program participants.
Aug 17, 2018
Journal Article
Genome-Wide Scan of Depressive Symptomatology in Two Representative Cohorts in the United States and the United Kingdom
This exploration of genomic associations with depression found no compelling evidence of a single genetic variant's significant role in depressive symptomatology.
Apr 17, 2018
Journal Article
Medical Oncologists' Experiences in Using Genomic Testing for Lung and Colorectal Cancer Care
More research is needed to determine whether the observed variation in genomic testing for lung and colorectal cancer reflects appropriate or inappropriate care.
Mar 13, 2017
Report
Population-scale sequencing and the future of genomic medicine: Learning from past and present efforts
This paper reflects on the variety and evolution of population-scale genome-sequencing initiatives, examining their diverse aims, activities, management and governance approaches, impacts, and policy and research implications.
Apr 29, 2016
Commentary
A New Model for Open Innovation: The Structural Genomics Consortium
Open innovation is often suggested as a solution to enhance productivity in under-performing areas of research. Now, the strengths and weaknesses of a new open innovation model in drug discovery have been evaluated.
Mar 25, 2014
News Release
The Structural Genomics Consortium, an Innovative Open-Access, Public–Private Partnership, Is a Viable Model for Drug ...
The Structural Genomics Consortium is a viable model for drug discovery that appeals to investors, not least for advantages in efficiency over current models of public or commercial health research.
Mar 10, 2014
Report
Structural Genomics Consortium Offers Knowledge Platform for Drug Discovery
An independent evaluation of the Structural Genomics Consortium (SGC) examined the strengths and weaknesses of its efforts to support drug discovery efforts through a unique, open access model of public-private collaboration.
Mar 10, 2014
Report
The Structural Genomics Consortium: A knowledge platform for drug discovery: A summary
This report summarises the results of an independent evaluation of the Structural Genomics Consortium, an open access model of public-private collaboration, conducted by RAND Europe with the Institute on Governance.
Mar 10, 2014

1
2
Next

RAND Topic:
Genomic Medicine

Topic Synonyms:
Genomics